TRIB TRINITY BIOTECH PLC IFRS
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31
Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY12.8%
TTM net income YoY77.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.9%
Net income 3-yr CAGR—
Margins
Gross margin47.6%
Operating margin0.1%
Net margin-6.3%
FCF margin20.2%
EBITDA margin0.1%
Returns
ROE-512.3%
ROA-4.9%
ROIC (approx.)0.1%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets101.7%
Debt / equity—
Current ratio3.08x
Interest coverage0.01x
Cash quality & payout
Operating cash flow / net income-3.72x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $61.55M | $56.83M | $62.52M | $81.15M | $101.98M |
| Cost of revenue | $40.11M | $37.38M | $45.25M | $47.70M | $53.40M |
| Gross profit | $21.44M | $19.45M | $17.27M | $33.45M | $48.58M |
| R&D expense | $4.54M | $4.38M | $4.14M | $4.50M | $5.08M |
| SG&A expense | $28.82M | $31.15M | $26.98M | $22.50M | $26.39M |
| Operating income | -$21.16M | -$27.05M | -$19.35M | $3.94M | $82,000 |
| Interest expense | $9.56M | $11.05M | $24.73M | $7.08M | $6.75M |
| Pretax income | -$30.73M | -$36.93M | -$43.78M | -$1.92M | -$6.63M |
| Income tax | $486,000 | -$59,000 | -$194,000 | -$74,000 | -$620,000 |
| Net income | -$31.79M | -$24.02M | -$41.01M | $875,000 | -$6.39M |
| EBITDA | -$20.96M | -$27.05M | -$19.35M | $41.94M | $122,000 |
| EPS (diluted) | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | — | 79.54M | 36.99M | 37.75M |
| Balance sheet | |||||
| Cash & equivalents | $5.17M | $3.69M | $6.58M | $25.91M | $27.33M |
| Receivables | $16.07M | $13.90M | $2.69B | $2.99M | $3.92M |
| Inventory | $19.37M | $19.93M | $22.50M | $29.12M | $30.22M |
| Current assets | $41.12M | $39.04M | $46.67M | $72.69M | $83.30M |
| PP&E, netmay include right-of-use assets (IFRS) | $4.62M | $1.89M | $5.68M | $5.92M | $8.55M |
| Total assets | $103.29M | $59.44M | $92.10M | $118.89M | $130.40M |
| Current liabilities | $32.09M | $15.04M | $17.34M | $100.49M | $27.06M |
| Short-term debt | — | $210,000 | — | $83.31M | — |
| Long-term debt | $210,000 | $210,000 | $210,000 | $83.31M | $82.66M |
| Total debt | $210,000 | $420,000 | $210,000 | $166.62M | $82.66M |
| Total liabilities | $138.47M | $83.38M | $94.28M | $119.21M | $132.62M |
| Shareholders' equity | -$35.18M | -$23.95M | -$2.18M | -$319,000 | -$2.22M |
| Net debt | -$4.96M | -$3.27M | -$6.37M | $140.71M | $55.34M |
| Cash flow statement | |||||
| Operating cash flow | -$4.19M | -$11.56M | -$921,000 | $13.24M | $23.75M |
| Capital expenditure | $405,000 | $803,000 | $1.10M | $1.81M | $3.18M |
| Free cash flow | -$4.60M | -$12.36M | -$2.02M | $11.43M | $20.58M |
| Investing cash flow | -$22.97M | $24.76M | -$5.98M | -$8.69M | -$10.20M |
| Financing cash flow | $28.81M | -$16.04M | -$12.32M | -$6.02M | -$2.72M |
| Depreciation & amortization | $204,000 | $0 | $0 | $38.00M | $40,000 |
| Stock-based compensation | $1.32M | $2.07M | $1.75M | $1.10M | $792,000 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.